Synthetic biology specialist GRO Biosciences started exploring strategic alternatives about six months after raising a series ...

The creation of the landmark GRO, known as "Ochre" - which fully compresses redundant, or "degenerate" codons, into a single codon - is described in a new study published on February 5th, 2025 in ...

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of the central nervous system (CNS)-penetrant therapeutics that are based on Trimtacs, the ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

The ISC class 12 Biology exam is one of the most important exams for students aiming to excel in science. Understanding the ...

The team was able to reach protein yields at the pool stage that couldn’t be achieved previously with a random integration approach.

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

From its base at the Milner Therapeutics Institute, TRIMTECH is developing a pipeline of potent, CNS (central nervous system) ...

Peptides designed by artificial intelligence restrict both drug-resistant bacteria and rapidly evolving viruses.

Collaboration Revenue: There was $2.3 million of collaboration revenue for the year ended December 31, 2024, as compared to no collaboration revenue for the year ended December 31, 2023. The increase ...

Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. The investment will support further development of ...